Time to progression and time to treatment failure in patients with triple-negative metastatic breast cancer receiving eribulin mesylate in a community oncology setting.
Claudio Faria
Employment or Leadership Position - Eisai
James Jackson
Research Funding - Eisai
Orsolya Lunacsek
Research Funding - Eisai
Kristin L. Hennenfent
Research Funding - Eisai